BC Week In Review | Jul 16, 2012
Company News

SRI International autoimmune news

The U.S. Department of Defense awarded SRI a one-year grant to develop an oral inhibitor of microRNA-326 (miR-326) to treat multiple sclerosis (MS). SRI said the product is in the early stage of development. Details...
BC Innovations | Jan 14, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-326 (miR-326) Studies in mice and in cell culture suggest that increasing miR-326 levels could help treat brain cancer. In a panel of...
BC Innovations | Oct 22, 2009
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) MicroRNA-326 (miRNA-326) A study in patients and in mice suggests that inhibiting miRNA-326 could help treat MS. Peripheral blood leukocytes isolated...
Items per page:
1 - 3 of 3